Newsfeeds - Spark Newswire

1 minute read

SINOVAC Announces COVID-19 Vaccine Approved For Emergency Use In Chile For Children And Adolescents

Today, 12:59 PM

SINOVAC Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced that CoronaVac®, an innovative, inactivated coronavirus

SVA

1 minute read

Inovio To Start Global Late-Stage COVID-19 Vaccine Trial

By Vandana Singh

Today, 12:59 PM

The regulatory authority of Brazil has signed off Inovio Pharmaceuticals Inc’s (NASDAQ:INO) global Phase 3 segment of its INNOVATE Phase 2/3…

INO

3 minute read

News

SINOVAC Announces Positive Data on Booster Shots of CoronaVac, Induces Strong Immune Response in Adult and Elderly Populations

By Benzinga Newsdesk

Today, 12:59 PM

SINOVAC Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today the publication of two papers, which are available on

SVA

1 minute read

EMA Starts Rolling Review Of Glaxo – Sanofi COVID-19 Vaccine

By Vandana Singh

Today, 12:59 PM

EMA's human medicines committee has kicked off a rolling review of a COVID-19 vaccine from Sanofi SA (NASDAQ:

CVAC

2 minute read

News

SINOVAC Receives Approval on Sabin Strain Based Inactivated Polio Vaccine To Support Global Polio Endgame Strategy

By Benzinga Newsdesk

Today, 12:59 PM

SINOVAC Biotech Ltd. (NASDAQ:SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced it received a drug registration approval from the

SVA

1 minute read

Lancet Study Shows BioNTech COVID-19 Vaccine Generates 10X Higher Antibody Levels Compared to Sinovac Shot

By Vandana Singh

Today, 12:59 PM

A new Hong Kong study has found that people fully vaccinated with the BioNTech SE (NASDAQ:BNTX) COVID-19 shot have ten…

BNTX

4 minute read

Sinovac Highlights Publication Of Phase I/II COVID-19 Study In The Lancet Infectious Diseases

By Bill Haddad

Today, 12:59 PM

- CoronaVac® is safe among the pediatric group aged 3 to 17 years old - CoronaVac can induce strong antibody responses in this pediatric group Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the

SVA